Download PDF
Thromb Haemost 2018; 118(04): 654-663
DOI: 10.1055/s-0038-1636535
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis

Sarah Goldman   *
1   Krakow Center for Medical Research and Technology, John Paul II Hospital, Kraków, Poland
,
Paulina Frączek   *
1   Krakow Center for Medical Research and Technology, John Paul II Hospital, Kraków, Poland
,
Krzysztof Szklanny
2   Department of Trauma and Orthopedics, St. Luke's Regional Hospital in Tarnów, Tarnów, Poland
,
Elżbieta Papuga-Szela
3   Immunology Outpatient Clinic, John Paul II Hospital, Krakow, Poland
,
Andrzej Stanisz
4   Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, Kraków, Poland
,
Anetta Undas
1   Krakow Center for Medical Research and Technology, John Paul II Hospital, Kraków, Poland
5   Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
› Author Affiliations
Further Information

Publication History

20 October 2017

11 January 2018

Publication Date:
04 April 2018 (online)

    Permissions and Reprints

Abstract

Background Prothrombotic clot phenotype may characterize patients developing deep vein thrombosis (DVT) despite pharmacological thromboprophylaxis. We studied the role of fibrin clot properties and its potential determinants in individuals who experienced DVT after lower limb injury.

Methods In a case–control study, we assessed 50 patients who developed DVT despite prophylactic use of low-molecular-weight heparins (the failed thromboprophylaxis group) after a lower limb injury, and three age- and sex-matched control groups, 50 patients each: (1) patients with trauma-related DVT without prior thromboprophylaxis; (2) individuals with unprovoked DVT; (3) patients without history of DVT (the no-DVT controls). Fibrin clot properties, along with thrombin concentration and α2-antiplasmin, were assessed following 3 months of anticoagulation in all DVT patients.

Results Compared with the no-DVT controls, the failed thromboprophylaxis group exhibited denser fibrin networks (12.8% lower clot permeability [Ks], p = 0.0008) and impaired fibrinolysis (46.2% longer clot lysis time [CLT], p = 0.0001 and 8% lower rate of D-dimer release from clots, p = 0.0008). In the unprovoked DVT, similar Ks and 14.9% shorter CLT (p = 0.02) were reported compared with the failed thromboprophylaxis group. The failed thromboprophylaxis patients had higher odds of having elevated peak thrombin generation (>241.5 nM, 90th percentile in the no-DVT controls; odds ratio [OR]: 3.62; 95% confidence interval [CI], 1.86–7.06; p = 0.002), and higher odds of having elevated α2-antiplasmin (>115.05%; OR: 3.38; 95% CI, 1.64–6.98; p = 0.001).

Conclusion Patients who experienced DVT despite thromboprophylaxis following lower limb trauma display a strongly prothrombotic fibrin clot phenotype, including increased clot density and hypofibrinolysis associated with higher plasma α2-antiplasmin.

Keywords

prothrombotic - fibrin - fibrinolysis - thromboprophylaxis - lower limb trauma

* Sarah Goldman and Paulina Frączek equally contributed to this work.


Supplementary Material

 

  • References

  • 1 Cohen AT, Gitt AK, Bauersachs R. , et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost 2017; 117 (07) 1326-1337
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Weitz JI, Jaffer IH. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Pol Arch Med Wewn 2016; 126 (09) 688-696
    PubMedGoogle Scholar
  • 3 Toker S, Hak DJ, Morgan SJ. Deep vein thrombosis prophylaxis in trauma patients. Thrombosis 2011; 2011: 505373
    CrossrefPubMedGoogle Scholar
  • 4 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 3-14
    CrossrefPubMedGoogle Scholar
  • 5 Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O'Donnell CJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res 2016; 145: 27-33
    CrossrefPubMedGoogle Scholar
  • 6 Potaczek DP, Jankowska EA, Wypasek E, Undas A. Iron deficiency: a novel risk factor of recurrence in patients after unprovoked venous thromboembolism. Pol Arch Med Wewn 2016; 126 (03) 159-165
    PubMedGoogle Scholar
  • 7 Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149 (06) 824-833
    CrossrefPubMedGoogle Scholar
  • 8 Douketis J, Ageno W, Carrier M, Kearon C. Managing challenging patients with venous thromboembolism: a practical, case-based approach. Pol Arch Intern Med 2017; 127 (01) 41-46
    PubMedGoogle Scholar
  • 9 Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg 2004; 240 (03) 490-496 , discussion 496–498
    CrossrefPubMedGoogle Scholar
  • 10 Undas A. Long-term anticoagulation in questions and answers. Pol Arch Med Wewn 2016; 126 (12) 1036-1039
    PubMedGoogle Scholar
  • 11 O'Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. Can J Surg 2003; 46 (02) 129-135
    PubMedGoogle Scholar
  • 12 Falck-Ytter Y, Francis CW, Johanson NA. , et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e278S-e325S
    CrossrefPubMedGoogle Scholar
  • 13 Venous thromboembolism: reducing the risk for patients in hospital. Clinical Guideline. National Institute for Health and Care Excellence; 2010 . Available at: https://www.nice.org.uk/guidance/cg92 . Accessed October 16, 2017
    PubMedGoogle Scholar
  • 14 Batra S, Kurup H, Gul A, Andrew JG. Thromboprophylaxis following cast immobilisation for lower limb injuries--survey of current practice in United Kingdom. Injury 2006; 37 (09) 813-817
    CrossrefPubMedGoogle Scholar
  • 15 Fleischer AE, Abicht BP, Baker JR, Boffeli TJ, Jupiter DC, Schade VL. American College of Foot and Ankle Surgeons' clinical consensus statement: risk, prevention, and diagnosis of venous thromboembolism disease in foot and ankle surgery and injuries requiring immobilization. J Foot Ankle Surg 2015; 54 (03) 497-507
    CrossrefPubMedGoogle Scholar
  • 16 Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med 2002; 347 (10) 726-730
    CrossrefPubMedGoogle Scholar
  • 17 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160 (22) 3415-3420
    CrossrefPubMedGoogle Scholar
  • 18 Spannagel U, Kujath P. Low molecular weight heparin for the prevention of thromboembolism in outpatients immobilized by plaster cast. Semin Thromb Hemost 1993; 19 (Suppl. 01) 131-141
    PubMedGoogle Scholar
  • 19 van Adrichem RA, Nemeth B, Algra A. , et al; POT-KAST and POT-CAST Group. Thromboprophylaxis after knee arthroscopy and lower-leg casting. N Engl J Med 2017; 376 (06) 515-525
    CrossrefPubMedGoogle Scholar
  • 20 Siudut J, Świat M, Undas A. Altered fibrin clot properties in patients with cerebral venous sinus thrombosis: association with the risk of recurrence. Stroke 2015; 46 (09) 2665-2668
    CrossrefPubMedGoogle Scholar
  • 21 Undas A, Zawilska K, Ciesla-Dul M. , et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114 (19) 4272-4278
    CrossrefPubMedGoogle Scholar
  • 22 Bridge KI, Philippou H, Ariëns R. Clot properties and cardiovascular disease. Thromb Haemost 2014; 112 (05) 901-908
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Zabczyk M, Plens K, Wojtowicz W, Undas A. Prothrombotic fibrin clot phenotype is associated with recurrent pulmonary embolism after discontinuation of anticoagulant therapy. Arterioscler Thromb Vasc Biol 2017; 37 (02) 365-373
    CrossrefPubMedGoogle Scholar
  • 24 Matusik PT, Matusik PS, Kornacewicz-Jach Z, Małecka B, Ząbek A, Undas A. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation. Int J Cardiol 2017; 243: 244-250
    CrossrefPubMedGoogle Scholar
  • 25 Ząbczyk M, Undas A. Plasma fibrin clot structure and thromboembolism: clinical implications. Pol Arch Intern Med 2017; 127 (12) 873-881
    CrossrefPubMedGoogle Scholar
  • 26 Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4 (05) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 27 Meltzer ME, Lisman T, de Groot PG. , et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116 (01) 113-121
    CrossrefPubMedGoogle Scholar
  • 28 Pankiw-Bembenek O, Zalewski J, Goralczyk T, Undas A. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012; 107 (03) 513-520
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010; 125 (04) 357-361
    CrossrefPubMedGoogle Scholar
  • 30 Kyrle PA, Kammer M, Eischer L. , et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost 2016; 14 (12) 2402-2409
    CrossrefPubMedGoogle Scholar
  • 31 Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost 2014; 112 (01) 32-42
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Undas A. How to assess fibrinogen levels and fibrin clot properties in clinical practice?. Semin Thromb Hemost 2016; 42 (04) 381-388
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Undas A. Prothrombotic fibrin clot phenotype in patients with deep vein thrombosis and pulmonary embolism: a new risk factor for recurrence. Bio Med Res Int 2017; 2017: 8196256
    PubMedGoogle Scholar
  • 34 Abdul S, Leebeek FW, Rijken DC, Uitte de Willige S. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences. Blood 2016; 127 (05) 538-545
    CrossrefPubMedGoogle Scholar
  • 35 Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. Semin Thromb Hemost 2017; 43 (02) 178-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Singh S, Houng A, Reed GL. Fibrinolytic system components uniquely affect the resolution of deep vein thrombosis: comparison of α2-antiplasmin and tissue plasminogen activator. Research and Practice in Thrombosis and Haemostasis 2017; 1 (Suppl. S1): 130 . The abstract book is available here: http://onlinelibrary.wiley.com/doi/10.1002/rth2.12012/epdf
    PubMedGoogle Scholar
  • 37 Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 5 (05) e97
    CrossrefPubMedGoogle Scholar
  • 38 Urano T, Suzuki Y. Thrombolytic therapy targeting alpha 2-antiplasmin. Circulation 2017; 135 (11) 1021-1023
    CrossrefPubMedGoogle Scholar
  • 39 Kremers RM, Peters TC, Wagenvoord RJ, Hemker HC. The balance of pro- and anticoagulant processes underlying thrombin generation. J Thromb Haemost 2015; 13 (03) 437-447
    CrossrefPubMedGoogle Scholar
  • 40 Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96 (05) 553-561
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296 (04) 397-402
    CrossrefPubMedGoogle Scholar
  • 42 Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96 (03) 988-995
    CrossrefPubMedGoogle Scholar
  • 43 Van Hylckama Vlieg A, Komanasin N, Ariëns RA. , et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119 (01) 169-175
    CrossrefPubMedGoogle Scholar
  • 44 Zee AA, van Lieshout K, van der Heide M, Janssen L, Janzing HM. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization. Cochrane Database Syst Rev 2017; 8: CD006681
    PubMedGoogle Scholar
  • 45 Siudut J, Grela M, Wypasek E, Plens K, Undas A. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J Thromb Haemost 2016; 14 (04) 784-793
    CrossrefPubMedGoogle Scholar
  • 46 Pieters M, Undas A, Marchi R, De Maat MP, Weisel J, Ariëns RA. ; Factor XIII And Fibrinogen Subcommittee Of The Scientific Standardisation Committee Of The International Society For Thrombosis And Haemostasis. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values. J Thromb Haemost 2012; 10 (10) 2179-2181
    CrossrefPubMedGoogle Scholar
  • 47 Fareed J, Hoppensteadt D, Walenga J. , et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 2003; 42 (12) 1043-1057
    CrossrefPubMedGoogle Scholar